Exhibit 99.1

FOR IMMEDIATE RELEASE
FSK Prices Public Offering of $1,000,000,000 3.400% Notes Due 2026
PHILADELPHIA, PA, December 3, 2020 – FS KKR Capital Corp. (NYSE: FSK) announced that it has priced an underwritten public offering of $1,000,000,000 in aggregate principal amount of its 3.400% unsecured notes due 2026 (the “Notes”). The Notes will mature on January 15, 2026 and may be redeemed in whole or in part at FSK’s option at any time at par plus a “make-whole” premium, provided that the Notes may be redeemed at par one month prior to their maturity. The offering is expected to close on December 10, 2020, subject to customary closing conditions.
BofA Securities, Inc., BMO Capital Markets Corp., ING Financial Markets LLC, MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., Truist Securities, Inc., J.P. Morgan Securities LLC, Deutsche Bank Securities Inc., HSBC Securities (USA) Inc., Mizuho Securities USA LLC and KKR Capital Markets LLC are acting as joint book-running managers for this offering. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, RBC Capital Markets, LLC, Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC are acting as joint lead managers for this offering. BNP Paribas Securities Corp., SG Americas Securities, LLC, Compass Point Research & Trading, LLC, ICBC Standard Bank Plc, R. Seelaus & Co., LLC, Keefe, Bruyette & Woods, Inc. and U.S. Bancorp Investments, Inc. are acting as co-managers for this offering.
FSK expects to use the net proceeds of this offering to repay outstanding indebtedness under its financing arrangements.
Other Information
Investors are advised to carefully consider the investment objectives, risks, charges and expenses of FSK before investing. The pricing term sheet dated December 3, 2020, the preliminary prospectus supplement dated December 3, 2020, and the accompanying prospectus dated May 3, 2019, each of which has been filed with the U.S. Securities and Exchange Commission (the “SEC”), contain this and other information about FSK and should be read carefully before investing.
The information in the pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. The pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release are not offers to sell any securities of FSK and are not soliciting an offer to buy such securities in any state or jurisdiction where such offer and sale is not permitted.
FSK’s shelf registration statement is on file and was deemed immediately effective upon filing with the SEC. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents FSK has filed with the SEC for more complete information about FSK and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, FSK, any underwriter or any dealer participating in the offering will arrange to send you the prospectus supplement and accompanying prospectus if you request it from BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, email: dg.prospectus_requests@bofa.com; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attn: Debt Capital Markets Syndicate, tel: 1-866-864-7760; ING Financial Markets LLC, 1133 Avenue of the Americas, New York, NY 10036, Attn: Investment Grade Syndicate Desk, fax: 646-424-6248, email: DCM.NewYork@ING.COM; MUFG Securities Americas Inc., 1221 Avenue of the Americas, Sixth Floor, New York, NY 10020; SMBC Nikko Securities America, Inc., 277 Park Avenue, New York, NY 10172, Attn: Debt Capital Markets tel: 888-868-6856, email: prospectus@smbcnikko-si.com; and Truist Securities, Inc., 303 Peachtree Street, Atlanta, GA 30308, Attn: Prospectus Department, tel: 800-685-4786, email: TSIdocs@Truist.com.